New subgroup data and further analyses of the aflibercept 8 mg clinical trial program to highlight durability results of extended dosing intervals, patient characteristics, and efficacy and safety in wet age-related macular degeneration and diabetic macular edema
18 presentations reinforce Regeneron’s commitment to patients with serious retinal diseases
TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection will be featured in 18 presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting from April 23-27. Among the presentations will be new subgroup data and further analyses of aflibercept 8 mg treatment from the pivotal PULSAR and PHOTON trials in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), as well as the Phase 2 CANDELA trial in wAMD.
“Our data presentations at ARVO build on the more than 20 years of industry-leading knowledge and dedicated research aimed at addressing the unmet needs of patients with serious retinal diseases,” said Boaz Hirshberg, M.D., Senior Vice President, Clinical Sciences General Medicine at Regeneron. “We look forward to sharing presentations on the efficacy and safety of EYLEA in multiple retinal diseases, as well as additional analyses of the pivotal aflibercept 8 mg trials – all of which reinforce our unwavering commitment to advancing retinal care for patients at risk of losing their vision.”
Notable podium presentations will highlight the pivotal aflibercept 8 mg trials PULSAR and PHOTON, respectively, in wAMD and DME with 48-week efficacy and safety results, in addition to an evaluation of baseline characteristics of patients randomized to aflibercept 8 mg who maintained their dosing intervals and those whose dosing intervals were shortened. A pooled safety analysis of aflibercept 8 mg across the PULSAR, PHOTON and CANDELA trials will also be presented.
Data from PHOTON and PULSAR were first presented at the American Academy of Ophthalmology’s annual meeting in September 2022. In February 2023, the U.S. Food and Drug Administration (FDA) accepted for Priority Review the Biologics License Application (BLA) for aflibercept 8 mg for treatment of patients with wAMD, DME and diabetic retinopathy with a target action date of June 27, 2023. Aflibercept 8 mg is investigational, and its safety and efficacy have not been fully evaluated by any regulatory authority.
Aflibercept 8 mg is being jointly developed by Regeneron and Bayer AG. In the U.S., Regeneron maintains exclusive rights to EYLEA and aflibercept 8 mg. Bayer has licensed the exclusive marketing rights outside of the U.S., where the companies share equally the profits from sales of EYLEA and future sales of aflibercept 8 mg following any regulatory approvals.
Aflibercept 8 mg and EYLEA presentations at ARVO:
Abstract title | Abstract | Lead author | Presentation date, time (CT), location |
Aflibercept 8 mg | |||
Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial | #2814Podium Presentation | Diana V. Do, M.D. | Tuesday, April 2512:30 – 12:45 PMLa Nouvelle AB |
Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial* | #461 Podium Presentation | Martin S. Spitzer, M.D. | Sunday, April 2312:15 – 12:30 PMLa Nouvelle AB |
Baseline disease characteristics of patients who maintained 12- and 16-week aflibercept 8 mg dosing versus patients with shortened treatment intervals through week 48 in the Phase 2/3 PHOTON trial | #2813Podium Presentation | David M. Brown, M.D., FACS | Tuesday, April 2512:15 – 12:30 PMLa Nouvelle AB |
Baseline disease characteristics in patients maintaining q12 and q16 dosing with aflibercept 8 mg versus patients with shortened treatment intervals: A Phase 3 PULSAR post hoc analysis* | #2239Poster Presentation | Paolo Lanzetta, M.D. | Monday, April 243:15 – 5:00 PMC0192 |
Pooled safety analysis of aflibercept 8 mg in the CANDELA, PHOTON, and PULSAR trials | #3724Poster Presentation | Eric Schneider, M.D. | Tuesday, April 25 3:30 – 5:15 PMC0501 |
Additional visual and anatomic outcomes of intravitreal aflibercept injection 8 mg versus 2 mg: A post hoc analysis of the Phase 2 CANDELA study | #2180Poster Presentation | Jordana G. Fein, M.D., M.S. | Monday, April 243:15 – 5:00 PMC0133 |
Intravitreal aflibercept 8 mg for diabetic macular edema: Week 48 efficacy outcomes by baseline demographics in the Phase 2/3 PHOTON trial | #2707Poster Presentation | Ghassan Ghorayeb, M.D. | Tuesday, April 25 8:45 – 10:30 AMB0529 |
Subgroup analyses from the Phase 3 PULSAR trial of aflibercept 8 mg in patients with treatment-naïve neovascular age-related macular degeneration* | #2238Poster Presentation | Sobha Sivaprasad, M.D. | Monday, April 243:15 – 5:00 PMC0191 |
Tolerability and safety of intravitreal aflibercept 8 mg in the Phase 3 PULSAR trial of patients with neovascular age-related macular degeneration* | #278 Poster Presentation | Jean-François Korobelnik, M.D., Ph.D. | Sunday, April 238:00 – 9:45 AMC0115 |
Intravitreal aflibercept 8 mg in patients with polypoidal choroidal vasculopathy (PCV): A Phase 3 PULSAR trial subgroup analysis* | #2240Poster Presentation | Tien Y. Wong, M.D. | Monday, April 243:15 – 5:00 PMC0193 |
EYLEA | |||
Efficacy of intravitreal aflibercept versus laser photocoagulation for retinopathy of prematurity: Results from the Phase 3 BUTTERFLEYE trial | #5126Podium Presentation | Darius M. Moshfeghi, M.D. | Thursday, April 2711:30 – 11:45 AM353-355 |
Impact of initial monthly doses of aflibercept on visual outcomes in eyes with diabetic macular edema in routine clinical practice in the US | #3646Poster Presentation | Nitish Mehta, M.D. | Tuesday, April 25 3:30 – 5:15 PMC0423 |
Impact of baseline vision on visual outcomes and vision-related functions in eyes with diabetic macular edema: A post hoc analysis of VISTA and VIVID trials | #2703 Poster Presentation | Mark Barakat, M.D. | Tuesday, April 25 8:45 – 10:30 AMB0525 |
Intravitreal aflibercept in routine clinical practice: 24-month results from the global treatment-naïve cohort with macular edema secondary to central retinal vein occlusion in the AURIGA study* | #1762Poster Presentation | Audrey Giocanti-Aurégan, M.D., Ph.D. | Monday, April 2411:30 AM – 1:15 PM C0221 |
Intravitreal aflibercept in routine clinical practice: 24-month results from the global cohort of pretreated patients with diabetic macular edema in the AURIGA study* | #2637Poster Presentation | Simone Donati, M.D. | Tuesday, April 25 8:45 – 10:30 AMB0459 |
Two-year results from a global observational study investigating proactive dosing regimens with intravitreal aflibercept in neovascular age-related macular degeneration (nAMD) in routine clinical practice: The XTEND study* | #462Podium Presentation | Clare C. Bailey, M.D. | Sunday, April 2312:30 – 12:45 PMLa Nouvelle AB |
Is there more to intravitreal aflibercept than anti-angiogenesis? Evaluating additional effects in DME through an in silico approach* | #2701Poster Presentation | Ricardo P. Casaroli-Marano, M.D., M.Sc., Ph.D. | Tuesday, April 258:45 – 10:30 AMB0523 |
A post hoc analysis of intravitreal aflibercept–treated patients from ARIES & ALTAIR applying treatment regimen criteria from TENAYA & LUCERNE* | #2223Poster Presentation | Michael Stewart, M.D. | Monday, April 243:15 – 5:00 PMC0176 |
*Bayer-run trial
About the Aflibercept 8 mg Clinical Trial ProgramPULSAR in wAMD and PHOTON in DME are double-masked, active-controlled pivotal trials that are being conducted in multiple centers globally. In both trials, patients were randomized into 3 treatment groups to receive either: aflibercept 8 mg every 12 weeks, aflibercept 8 mg every 16 weeks, or EYLEA every 8 weeks. The lead sponsors of the trials were Bayer for PULSAR and Regeneron for PHOTON.
Patients treated with aflibercept 8 mg in both trials had 3 initial monthly doses, and patients treated with EYLEA received 5 initial monthly doses in PHOTON and 3 in PULSAR. In the first year, patients in the aflibercept 8 mg groups could have their dosing intervals shortened down to an every 8-week interval if protocol-defined criteria for disease progression were observed. Intervals could not be extended until the second year of the study, with those results still to be assessed. Patients in all EYLEA groups maintained a fixed 8-week dosing regimen throughout their participation in the trials.
CANDELA was a Phase 2 trial investigating the safety and efficacy of aflibercept 8 mg extended dosing regimens compared to EYLEA in wAMD patients.
About wAMD and DMEwAMD is a retinal disease that may affect people as they age. It occurs when abnormal blood vessels grow and leak fluid under the macula, the part of the eye responsible for sharp central vision and seeing fine detail. This fluid can damage and scar the macula, which can cause vision loss. An estimated 1.1 million Americans have wAMD, and this number is expected to double by 2050.
DME is a common complication in eyes of people living with diabetes. DME occurs when high levels of blood sugar lead to damaged blood vessels in the eye that leak fluid into the macula. This can lead to vision loss and, in some cases, blindness. Of the nearly 28 million American adults living with diabetes, an estimated 1.2 million have DME.
About EYLEAEYLEA is a VEGF inhibitor formulated as an injection for the eye. It is designed to block the growth of new blood vessels and decrease the ability of fluid to pass through blood vessels (vascular permeability) in the eye by blocking VEGF-A and placental growth factor (PLGF), two growth factors involved in ocular angiogenesis. The EYLEA safety and efficacy profile is supported by a robust body of research that includes eight pivotal Phase 3 trials, more than 11 years of real-world experience and greater than 57 million EYLEA injections globally.
IMPORTANT EYLEA SAFETY INFORMATION AND INDICATIONS
INDICATIONSEYLEA (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Retinopathy of Prematurity (ROP) (0.4 mg [0.01 mL]).
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS